COVID-19 ‘cocktail’ therapy moves to clinical trial

Hospital News

A therapeutic, two-antibody COVID-19 treatment “cocktail” from Regeneron and the Biomedical Advanced Research and Development Authority moved to its first clinical trial, the developers earlier this month announced.

The REGN-COV2 treatment contains two neutralizing monoclonal antibodies. It is believed to have the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2.

Products You May Like

Articles You May Like

3M issues guidance on identifying counterfeit N95 respirators
U.S. commits $4 billion to international COVAX vaccine alliance
Study: Hospitals’ financial struggles continued in January
Lifespan, Care New England ink deal to create academic medical system with Brown University
AHA receives CDC grants to promote COVID-19 vaccine confidence, prevent infection

Leave a Reply